QSAM Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Common Stock, Preferred Stock and Warrants (Details Narrative)

Common Stock, Preferred Stock and Warrants (Details Narrative) - USD ($)					12 Months Ended
	Dec. 31, 2020	Dec. 29, 2020	Dec. 03, 2020	Sep. 04, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number shares issued during period					17,392,343
Debt conversion, value					$ 3,441,401
Conversion price per share	$ 0.22				$ 0.22
Description of reverse stock spilt				The Company completed a 25:1 reverse stock split of its common shares.	The Company also effected a 25:1 reverse stock split
Loss on convertible debt and other liabilities converted to equity					$ 834,903
Preferred stock, shares issued	600				600	600
Preferred stock, shares outstanding	600				600	600
Convertible preferred stock conversion price per share	$ 0.16				$ 0.16
Preferred stock dividend percentage					6.00%
Preferred stock liquidation preference equal to aggregate purchase price plus accrued dividends	$ 600,000				$ 600,000
Number of warrants expired					46,154
Convertible preferred stock consent percentage					67.00%
Redemption term					2 years
Debt conversion into shares					534,815
Subscription receivable	$ 25,000				$ 25,000
Expected term					5 years
Expected dividend yield rate					0.00%
Expected volatility rate					149.67%
Expected risk-free rate					1.61%
Number of warrants							6,000
Exercise price of warrants							$ 1.00
Average remaining term in years							5 years
Series B Convertible Preferred Stock [Member]
Debt conversion, value					$ 156,000
Preferred stock, shares issued	2,500				2,500
Preferred stock, shares outstanding	281				281
Convertible preferred stock conversion price per share	$ 1,000	$ 0.16			$ 1,000
Preferred stock dividend percentage		10.00%
Preferred stock liquidation preference equal to aggregate purchase price plus accrued dividends		$ 1,000
Debt conversion into shares					156
Subscription receivable	$ 25,000				$ 25,000
Debt conversion description					As of December 31, 2020, 281 shares of Series B Stock were issued and outstanding in connection with the issuance of 156 shares upon the conversion of a note payable in the amount $156,000, inclusive of unpaid and accrued interest and the sale of 125 shares for total prices of $125,000, $25,000 of which was received in 2021 and recorded as a subscription receivable as of December 31, 2020.
Series B Convertible Preferred Stock [Member] \| New Capital [Member]
Debt conversion, value					$ 125,000
Series B Convertible Preferred Stock [Member] \| Maximum [Member]
Number of issuance of authorized shares		2,500
Series E-1 Preferred Stock [Member]
Common stock earnout			8,500,000
Fair value of vested in period			$ 5,340,000
Expected term			4 years
Expected dividend yield rate			0.00%
Expected volatility rate			96.12%
Expected risk-free rate			27.00%
Stock based compensation vesting description			Since the vesting period began on December 30, 2020, compensation expense as of December 31, 2020 was not significant.
Series E-1 Preferred Stock [Member] \| Five Individuals [Member]
Number shares issued during period	7,650
Debt conversion, value	$ 3,900,000
Debt conversion into shares	7,650,000
Series E-1 Preferred Stock [Member] \| Maximum [Member]
Number of issuance of authorized shares			8,500
Several Service Agreement [Member]
Compensation expense					258,667	$ 115,714
Bridge Notes [Member]
Debt conversion, value					$ 3,017,499
Debt conversion into shares					13,312,175
Common Stock [Member]
Number shares issued during period					17,392,343
Debt conversion into shares					13,312,175
Common Stock [Member] \| Unrelated Parties [Member]
Debt conversion, value					$ 68,373
Common Stock [Member] \| Related Parties [Member]
Debt conversion, value					271,210
Common Stock [Member] \| Bridge Notes [Member]
Debt conversion, value					$ 495,320
Warrant [Member]
Number of warrants expired					80,000	81,340
Number of warrants